title: Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation.
abstract: A multicentric phase 2 study was conducted to determine the efficiency and the tolerance of imatinib mesylate in children with chronic myelogenous leukemia (CML) in advanced phase of the disease, in relapse after stem cell transplantation, or in case of failure to an interferon alpha-based regimen. In all, 30 children from eight European countries were enrolled. In 18 children assessable for hematologic response, imatinib mesylate induced complete hematologic response in eight (80%) of the 10 patients included in chronic phase and in six (75%) of eight enrolled in advanced phase of the disease with acceptable toxicity. In 27 patients assessable for cytogenetic response, imatinib mesylate induced disappearance of Philadelphia chromosome-positive bone marrow cells in 12 (60%) of 20 children included in chronic phase and in two (29%) of seven included in advanced phase. A reduction of the bcr-abl/abl ratio to less than 10(-4) was achieved in 11 (50%) of the children included in chronic phase. Estimated 12-month overall survival rate was 95% (95% CI, 87-100%) for the patients included in chronic phase and 75% (95%CI, 45-100%) for those enrolled in advanced phase. Imatinib mesylate is well tolerated and molecular remission can be achieved in children with CML.
authors.affiliation: Department of Hematology, CHU la Milétrie, Poitiers, France. f.millot@chu-poitiers.fr
authors.forename: F
authors.initials: F
authors.lastname: Millot
authors.forename: J
authors.initials: J
authors.lastname: Guilhot
authors.forename: B
authors.initials: B
authors.lastname: Nelken
authors.forename: T
authors.initials: T
authors.lastname: Leblanc
authors.forename: E S
authors.initials: ES
authors.lastname: De Bont
authors.forename: A N
authors.initials: AN
authors.lastname: Békassy
authors.forename: H
authors.initials: H
authors.lastname: Gadner
authors.forename: S
authors.initials: S
authors.lastname: Sufliarska
authors.forename: J
authors.initials: J
authors.lastname: Stary
authors.forename: H
authors.initials: H
authors.lastname: Gschaidmeier
authors.forename: F
authors.initials: F
authors.lastname: Guilhot
authors.forename: M
authors.initials: M
authors.lastname: Suttorp
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D004334:Drug Administration Schedule; D005060:Europe; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000068877:Imatinib Mesylate; D007223:Infant; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012008:Recurrence; D012074:Remission Induction; D033581:Stem Cell Transplantation; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate